? ?Lidocaine (CAS 137-58-6) | Pharmaceutical-Grade Local Anesthetic & Antiarrhythmic Agent? ?

?? ?Product Overview?

?Lidocaine? (CAS 137-58-6), also known as ?Xylocaine?, is a widely used ?amide-type local anesthetic? and ?class IB antiarrhythmic drug? with the molecular formula ?C??H??N?O? and a molecular weight of ?234.34?. This white crystalline powder (purity ≥99%) acts by blocking voltage-gated sodium channels, providing rapid and reversible nerve impulse inhibition. It is essential for both clinical anesthesia and cardiac arrhythmia management, with high solubility in organic solvents and stability under standard storage conditions.

?Key Functions?:

• Induces ?local anesthesia? for surgical, diagnostic, and dermatological procedures.

• Treats ?ventricular arrhythmias? caused by acute hemodynamic instability.

• Serves as a ?pharmaceutical intermediate? or reference standard.

?Target Industries?: Pharmaceuticals, clinical healthcare, and biomedical research.

? ?Key Advantages?

?? ?Applications?

• ?Surface Anesthesia?: Pre-procedure mucosal numbing (e.g., endotracheal intubation).

• ?Infiltration/Regional Anesthesia?: Minor surgeries and pain management.

• ?Cardiac Care?: Emergency treatment of ventricular tachycardia/fibrillation.

• ?Dermatology?: EMLA cream for pre-IV catheterization skin numbing (45–60 min application).

?? ?Quality Assurance?

• ?Testing Standards?: Complies with ?USP/EP? pharmacopeial guidelines.

• ?Analytical Methods?: Validated via ?HPLC, NMR?, and ?mass spectrometry?.

• ?Packaging?: 1kg–25kg customizable batches (moisture-proof, vacuum-sealed).

?? ?Market Insights?

The global local anesthetics market is projected to grow at ?6.1% CAGR (2025–2030)?, driven by rising surgical volumes and demand for non-opioid pain management. Lidocaine remains a cornerstone in emergency medicine, with Asia-Pacific emerging as a key production hub due to cost-efficient synthesis.